ArticleThoracic cancer2025

Role of TP53 Mutations and EGFR Amplification in Risk Stratification of Early-Stage EGFR-Mutated Non-Small Cell Lung Cancer With Immunohistochemistry as a Surrogate Marker.

Meejeong Kim et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.